Research map: HER1–HER4 expression and co-expression in advanced urothelial carcinoma

Back to the article

Papers in this map

  1. Comprehensive molecular characterization of urothelial bladder carcinoma · Perou, Charles · 2019 · 3109 citations · Cited by this paper
  2. Mapping the HER-family landscape in advanced urothelial carcinoma · A. Moradi · 2026 · Cites this paper
  3. 61eP Radiotherapy combined with PARP inhibition in BRCA-mutated breast cancer: A systematic review of clinical outcomes and toxicity · 2026 · Related
  4. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer · A. Gordon Robertson · 2017 · 2558 citations · Cited by this paper
  5. Nectin-4 and Trop-2 expression in collecting duct carcinoma: new promising therapeutic targets · 2026 · Related
  6. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer · Aurélie Kamoun · 2019 · 1412 citations · Cited by this paper
  7. 149P Adjuvant radiotherapy outcomes for early stage (stage 1c-2) clear cell ovarian carcinoma in Edinburgh cancer centre · 2026 · Related
  8. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer · David James McConkey · 2015 · 281 citations · Cited by this paper
  9. 213P Glandular tissue–based versus anatomical landmark–based CTV delineation in postoperative breast cancer radiotherapy: A dosimetric comparison · 2026 · Related
  10. Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2–Positive Metastatic Bladder Cancer · Thomas B. Powles · 2017 · 208 citations · Cited by this paper
  11. 194eP Ovarian cancer during pregnancy: Maternal and fetal outcomes from a systematic review and meta-analysis · 2026 · Related
  12. Assessment of Luminal and Basal Phenotypes in Bladder Cancer · Charles Chuanhai Guo · 2020 · 176 citations · Cited by this paper
  13. 67RO Single-cell and TCR profiling reveals pre-existing cytotoxic CD8 T cell clonal expansion and peripheral–tumor dissociation associated with response to PD-1-based therapy in hepatocellular carcinoma · 2026 · Related
  14. Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer · Xinan Sheng · 2025 · 95 citations · Cited by this paper
  15. 219P Clinical profile and treatment outcomes of lymphoma patients: A retrospective cohort study · 2026 · Related
  16. HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder · Zak Latif · 2003 · 85 citations · Cited by this paper
  17. A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma) · 2026 · Related
  18. Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases · Truls Gårdmark · 2005 · 58 citations · Cited by this paper
  19. 152P Efficacy and safety of relacorilant + nab-paclitaxel in patients aged ≥65 years with platinum-resistant ovarian cancer (PROC) in the phase III ROSELLA study (GOG-3073, ENGOT-ov72, APGOT-Ov10) · 2026 · Related
  20. The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers · Avisek Majumder · 2021 · 55 citations · Cited by this paper
  21. 232eP GLP-1 receptor agonists and risk of incident endometrial, colorectal, and hepatocellular cancer: A systematic review and meta-analysis · 2026 · Related
  22. HER2 and urothelial carcinoma: current understanding and future directions · Daniele Raggi · 2025 · 28 citations · Cited by this paper
  23. Immunohistochemical expression of HER1, HER3, and HER4 in HER2‐positive breast cancer patients treated with trastuzumab‐containing neoadjuvant chemotherapy · Kan Yonemori · 2010 · 20 citations · Cited by this paper
  24. Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial · Thomas Powles · 2025 · 11 citations · Cited by this paper
  25. SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma · Thomas B. Powles · 2025 · 9 citations · Cited by this paper
  26. Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer · Ziyu Chen · 2025 · 8 citations · Cited by this paper
  27. HER3 promotes triple-negative breast cancer progression by upregulating PHF8 via miR-34b-5p-dependent mechanism · Hui Lyu · 2025 · 1 citation · Cited by this paper
  28. Untitled · Cited by this paper

Source: OpenAlex (CC0)